peptide
LL-37
moderateResearch Use OnlyInjection
Your body's natural antibiotic peptide. Fights bacteria, viruses, and fungi, breaks up biofilms, and supports wound healing while modulating immune response.
Key facts
- Classification
- LL-37 is the only human cathelicidin-derived antimicrobial peptide.
- Primary benefits
- Immune Support (8/10) · Inflammation (7/10) · Injury Healing (5/10)
- Administration
- Injection
- Doses studied
- 50-100 mcg subq daily, injected near the infection site. Cycle for 2-4 weeks.
- Evidence strength
- Moderate — 20 peer-reviewed studies
- Stacks well with
- Thymosin Alpha-1, BPC-157, KPV
- Legal status
- Research Use Only · not prescribable in US
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 20
- Stacks with
- 3 peptides
- Regulatory
- Research Use Only
Scientific overview
LL-37 is the only human cathelicidin-derived antimicrobial peptide. This 37-residue amphipathic α-helical peptide exhibits broad-spectrum antimicrobial activity through membrane disruption. Also promotes chemotaxis, angiogenesis, TLR modulation, wound healing, and biofilm disruption.
Goal coverage · LL-37
🛡️ Immune Support8/10
🧊 Inflammation7/10
🩹 Injury Healing5/10
🫃 Gut Health4/10
Medical oversight strongly recommendedNot safe during pregnancy· 3 contraindications